Dyadic International Establishes At-the-Market Equity Offering Program

Dyadic International ( (DYAI) ) has shared an announcement.

On March 6, 2026, Dyadic International, Inc. entered into an at-the-market issuance sales agreement with Craig-Hallum Capital Group LLC, allowing the company to sell up to $4,237,818 of its common stock from time to time through the sales agent under an existing shelf registration. The shares may be sold via various at-the-market methods on Nasdaq or other trading markets at prevailing, related or negotiated prices, with Dyadic retaining full discretion over whether, when and how much stock to sell.

Under the agreement, Craig-Hallum will receive a commission of up to 3.0% of the gross sales price of any shares sold and will be reimbursed for certain expenses, while benefiting from indemnification and contribution protections against specified liabilities. The arrangement provides Dyadic with flexible, on-demand access to equity capital, though neither the company nor the agent is obligated to proceed with sales, and the offering can be suspended or terminated at any time by either party subject to agreed conditions.

The most recent analyst rating on (DYAI) stock is a Sell with a $0.84 price target. To see the full list of analyst forecasts on Dyadic International stock, see the DYAI Stock Forecast page.

Spark’s Take on DYAI Stock

According to Spark, TipRanks’ AI Analyst, DYAI is a Neutral.

The score is held down primarily by weak financial performance (persistent losses, ongoing cash burn, and higher leverage) and bearish technical trends (price below major moving averages with negative MACD). Earnings-call execution milestones and supportive corporate events improve the outlook, but near-term fundamentals and funding/dilution risk remain key constraints.

To see Spark’s full report on DYAI stock, click here.

More about Dyadic International

Dyadic International, Inc. is a biotechnology company that develops and licenses proprietary technologies for the discovery, development, manufacture and sale of biological products. The company primarily focuses on leveraging its technology platforms to produce vaccines, antibodies and other therapeutic proteins for pharmaceutical and related life sciences markets.

Average Trading Volume: 70,639

Technical Sentiment Signal: Sell

Current Market Cap: $27.51M

See more data about DYAI stock on TipRanks’ Stock Analysis page.